C. Lovly

C. Raymond, Y. Shyr, C. Lovly, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Serine 379 Signaling through Autophosphorylation of Regulation of Chk2 Ubiquitination and

H. Piwnica-Worms, C. Lovly, C. Ryan, 2014 .

Regulation of Chk2 Ubiquitination and Signaling through Autophosphorylation of Serine 379

H. Piwnica-Worms, C. Lovly, C. Ryan, 2008, Molecular and Cellular Biology.

, Saeko Serine 379 Signaling through Autophosphorylation of Regulation of Chk 2 Ubiquitination and

H. Piwnica-Worms, C. Lovly, C. Ryan, 2008 .

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Benjamin P. Brown, J. Ross, J. Meiler, 2019, Clinical Cancer Research.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy

P. Stephens, J. Ross, J. Sosman, 2018, Pigment cell & melanoma research.

Tumor Heterogeneity and Therapeutic Resistance.

R. Salgia, C. Lovly, A. Salama, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Non – Small Cell Lung Cancer, Version 3.2022

Joe Y. Chang, D. Ettinger, L. Chirieac, 2022 .

Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

T. Shaffer, C. Lovly, Ying Yan, 2020, JTO clinical and research reports.

Expanding Horizons for Treatment of Early-Stage Lung Cancer.

C. Lovly, 2022, The New England journal of medicine.

Combating acquired resistance to tyrosine kinase inhibitors in lung cancer.

C. Lovly, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment-A catalogue of clinically relevant somatic mutations in lung cancer.

W. Pao, M. Levy, J. Andrews, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

P. Stephens, D. Lipson, V. Miller, 2014, Cancer discovery.

Tumors Harbor Multiple Potentially Actionable Kinase Fusions

P. Stephens, D. Lipson, V. Miller, 2014 .

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

H. Wakelee, J. Nieva, T. Shaffer, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer.

C. Rudin, J. Minna, J. Sage, 2020, Cancer discovery.

Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry.

J. Gross, H. Piwnica-Worms, C. Lovly, 2007, Rapid communications in mass spectrometry : RCM.

Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

P. Hegde, J. Sage, G. Frampton, 2022, bioRxiv.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.

C. Lovly, M. Harkenrider, N. Pennell, 2022, Clinical lung cancer.

The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas.

C. Lovly, L. Ratner, L. Bernal-Mizrachi, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

J. Sosman, Douglas B. Johnson, I. Puzanov, 2015, Cancer Immunology Research.

Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer.

Gabor T. Marth, Alissa M. Weaver, G. Marth, 2022, Cell systems.

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

U. Rix, A. Marusyk, C. Lovly, 2022, Science Signaling.

Melanoma driver mutations and immune therapy

R. Sullivan, J. Sosman, Douglas B. Johnson, 2016, Oncoimmunology.

Longitudinal monitoring of circulating tumor DNA and peripheral T cell repertoire in patients with small cell lung cancer.

Dan DiPasquo, C. Raymond, T. Shaffer, 2017 .

Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer

P. Gonzalez-Ericsson, Douglas B. Johnson, J. Balko, 2020, medRxiv.

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.

M. Ladanyi, M. Berger, C. Rudin, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.

C. Lovly, W. Iams, 2018, Cancer discovery.

Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute – Designated Comprehensive Cancer Center

Wiesner, Douglas, Balko, 2021 .

Potentially actionable kinase fusions in inflammatory myofibroblastic tumors.

P. Stephens, D. Lipson, V. Miller, 2013 .

A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.

W. Pao, H. Wakelee, C. Liang, 2014 .

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non–Small Cell Lung Cancer

C. Lovly, W. Iams, 2015, Cancer journal.

Cancer Hallmarks Define a Continuum of Plastic Cell States between Small Cell Lung Cancer Archetypes

V. Quaranta, D. Tyson, A. Simmons, 2021, bioRxiv.

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition

M. Fassan, Gianpiero di Leva, M. Garofalo, 2020, EMBO molecular medicine.

Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

A. Shaw, Ryohei Katayama, C. Lovly, 2015, Clinical Cancer Research.

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

William Pao, Zhongming Zhao, Ronglai Shen, 2014, Nature Medicine.

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

A. Shaw, R. Doebele, D. Proia, 2013, Cancer discovery.

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

William Pao, Michael Hölzel, Martin Peifer, 2011, Clinical Cancer Research.

Mechanisms of receptor tyrosine kinase activation in cancer

C. Lovly, Z. Du, 2018, Molecular Cancer.

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

Amanda R. Kulick, M. Ladanyi, W. Pao, 2017, Cancer research.

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

M. Krasnow, Y. Pommier, C. Rudin, 2020 .

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking

B. Reva, L. Borsu, M. Ladanyi, 2014, Clinical Cancer Research.

Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013, Clinical Cancer Research.

A 75-year-old man with progressive bronchioalveolar carcinoma.

C. Lovly, L. Horn, K. Reckamp, 2013, Seminars in oncology.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Yu Shyr, Jonathan M Irish, Anna E Vilgelm, 2016, Nature Communications.

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Roman K. Thomas, W. Pao, C. Liang, 2011, Cancer research.

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

N. Yeh, B. Kavanagh, K. Beal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanisms of receptor tyrosine kinase activation in cancer

C. Lovly, Z. Du, 2018, Molecular Cancer.

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

M. Berger, J. Meiler, D. Solit, 2017, Cancer discovery.

NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

D. Berry, T. Choueiri, R. Carlson, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.

Amber M. Johnson, J. Sklar, S. Ganesan, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer

E. Ziv, M. Aldrich, M. Hellmann, 2021, Clinical Cancer Research.

Established, emerging and elusive molecular targets in the treatment of lung cancer

C. Lovly, J. Gallant, 2018, The Journal of pathology.

Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.

Gyan Bhanot, Shridar Ganesan, G. Bhanot, 2017, JCO precision oncology.

Major milestones in translational oncology

H. Earl, E. Diamandis, J. Schalken, 2016, BMC Medicine.

Therapeutics , Targets , and Chemical Biology Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

E. Stanchina, Roman K. Thomas, W. Pao, 2011 .

Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

Benjamin P. Brown, M. Ladanyi, J. Meiler, 2021, Nature Communications.

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance

A. Hutson, M. Seshadri, C. Lovly, 2020, Cancers.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

S. Asthana, E. Collisson, J. Riess, 2015, Nature Medicine.

Molecular Pathways Molecular Pathways : Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

A. Shaw, C. Lovly, Christine M Lovly, 2014 .

New approaches to small cell lung cancer therapy : from the laboratory to the clinic.

M. Krasnow, Y. Pommier, C. Rudin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

E. Sokol, K. Abhishek, S. Ganesan, 2019, The oncologist.

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.

C. Lovly, L. Horn, P. Lammers, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition

Zhongming Zhao, C. Lovly, J. Gilbert, 2019, npj Precision Oncology.

The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas

C. Lovly, L. Ratner, L. Bernal-Mizrachi, 2006 .

Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Gregory Riely, C. Lovly, Helena A. Yu, 2014, Clinical Cancer Research.

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Roman K. Thomas, W. Pao, R. Küppers, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical See commentary by Crystal and Shaw , p . 4479 Differential Protein Stability and ALK Inhibitor Sensitivity of EML 4-ALK Fusion Variants

Roman K. Thomas, W. Pao, M. Peifer, 2012 .

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.

F. Hodi, S. Gettinger, T. Mok, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids

Martin Vingron, Thomas Zander, Viktor Achter, 2014, Nature Communications.

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation.

H. Piwnica-Worms, C. Lovly, J. Schwarz, 2003, Molecular cancer research : MCR.

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

V. Miller, Siraj M. Ali, C. Lovly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.

P. Stephens, S. Ou, V. Miller, 2017, Lung cancer.

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

S. Ou, V. Miller, Siraj M. Ali, 2017, Lung cancer.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Jens Meiler, Taofeek K Owonikoko, Jonathan H Sheehan, 2016, Cancer discovery.

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

M. Ladanyi, M. Kris, J. Meiler, 2015, Cancer discovery.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

William Pao, Vandana G Abramson, Jill Gilbert, 2014, The oncologist.

MAP 2 K 1 ( MEK 1 ) Mutations De fi ne a Distinct Subset of Lung Adenocarcinoma Associated with Smoking

B. Reva, L. Borsu, M. Ladanyi, 2015 .

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

W. Pao, N. Gray, D. Colvin, 2016, Cancer research.

EPHA2BlockadeOvercomesAcquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

W. Pao, N. Gray, D. Colvin, 2016 .

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties

Michael A. Davies, C. Lovly, Huiqin Chen, 2018, Molecular Cancer Research.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

H. Varmus, M. Ladanyi, M. Kris, 2018, Proceedings of the National Academy of Sciences.

YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

H. Varmus, M. Ladanyi, M. Kris, 2018, bioRxiv.

Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC

C. Lovly, L. Horn, 2012, Current Treatment Options in Oncology.

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

H. Ji, Roman K. Thomas, W. Pao, 2016, Clinical Cancer Research.

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.

C. Lovly, Heidi Chen, Megan L. Hames, 2016, Lung cancer.

Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013 .

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

C. Lovly, W. Iams, 2015, Clinical Cancer Research.

Translating genomic information into clinical medicine: Lung cancer as a paradigm

William Pao, Mia A Levy, W. Pao, 2012, Genome research.

Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

X. Chen, Zhongming Zhao, M. Ladanyi, 2014, Molecular Cancer Therapeutics.

Update on HER1-3 in advanced non-small-cell lung cancer.

C. Lovly, L. Horn, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer in 2010: One size does not fit all

D. Carbone, C. Lovly, David P. Carbone, 2011, Nature Reviews Clinical Oncology.

Fragments of ATM which have dominant-negative or complementing activity

Y. Shiloh, T. Pandita, C. Lovly, 1997, Molecular and cellular biology.

Severity of illness scores at presentation predict ICU admission and mortality in COVID-19

B. Rini, Y. Shyr, C. Lovly, 2021, Journal of emergency and critical care medicine.

Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.

C. Lovly, H. Niu, M. Humphries, 2022, Clinical lung cancer.

A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study.

Sharyn I. Katz, D. Mankoff, H. Wakelee, 2021, The oncologist.

Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.

D. Planchard, C. Lovly, Helena A. Yu, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors

P. Cin, C. Lovly, J. Hornick, 2015, Modern Pathology.

Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC

L. Coussens, V. Quaranta, D. Tyson, 2021, Journal of Thoracic Oncology.

Framework for Implementing and Tracking A Molecular Tumor Board at an NCI-Designated Comprehensive Cancer Center.

Neha M Jain, Douglas B. Johnson, J. Balko, 2021, The oncologist.

My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information

Fei Ye, Sheau-Chiann Chen, Nunzia Bettinsoli Giuse, 2016, CRI.

Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies

A. Iafrate, R. Sullivan, J. Sosman, 2015, Cancer Immunology Research.

Guiding Oncology Patients Through the Maze of Precision Medicine

Christine M. Micheel, Mia A. Levy, Nunzia Bettinsoli Giuse, 2016, Journal of health communication.

Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

William Pao, Mark C. Kelley, Ann Richmond, 2012, PloS one.

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

J. Neal, H. Wakelee, C. Liang, 2018, Clinical Cancer Research.

Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.

R. Sullivan, Dennie T. Frederick, J. Sosman, 2016 .

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome12

Christine M. Micheel, Mia A. Levy, M. Levy, 2016, Translational oncology.

1OComprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types

S. Ikeda, S. Ganesan, S. Ou, 2017 .

Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.

J. Warner, J. Bordeaux, C. Lovly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors

C. Lovly, C. Meador, 2015, Nature Medicine.

Analyzing Phospho-signaling in Human Glioblastoma Cell Lines Using Ex Vivo Culture

Rebecca A. Ihrie, C. Lovly, J. Irish, 2017 .

Tumor Heterogeneity and Therapeutic Resistance.

R. Salgia, C. Lovly, A. Salama, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Alignment, Segmentation and Neighborhood Analysis in Cyclic Immunohistochemistry Data Using CASSATT

Rebecca A. Ihrie, L. Coussens, C. Lovly, 2022, bioRxiv.

Managing Resistance to EFGR- and ALK-Targeted Therapies.

P. Iyengar, C. Lovly, J. Gainor, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

My Cancer Genome: Coevolution of Precision Oncology and a Molecular Oncology Knowledgebase

Neha M Jain, Kathleen F. Mittendorf, M. Levy, 2021, JCO clinical cancer informatics.

SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors

M. Ladanyi, S. Toyooka, Gregory Riely, 2022, JCO precision oncology.

Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

M. Berger, J. Meiler, D. Solit, 2019, Cancer discovery.

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

Benjamin P. Brown, J. Meiler, C. Lovly, 2022, bioRxiv.

A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors

H. Wakelee, C. Liang, C. Lovly, 2014 .

Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases.

C. Raymond, C. Lovly, C. Vnencak-Jones, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC

P. Massion, S. Antic, T. Shaffer, 2020, JTO clinical and research reports.

Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer.

C. Lovly, H. Qiao, 2016, Cancer discovery.

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

Allison P. Heath, Marilyn M. Li, Jena V. Lilly, 2022, Scientific Reports.

Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer

V. Velculescu, V. Anagnostou, J. White, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer.

L. Coussens, V. Quaranta, D. Tyson, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK

J. Neal, H. Wakelee, C. Liang, 2016 .

FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study

J. Nieva, R. Camidge, R. Doebele, 2021, Journal of Thoracic Oncology.

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review

C. Lovly, A. Desai, 2023, Translational lung cancer research.

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

H. Wakelee, S. Ramalingam, C. Lovly, 2021 .

N-[18F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer.

C. Lovly, Michael L. Nickels, J. Buck, 2020, Bioorganic & medicinal chemistry letters.

NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).

A. Iafrate, R. Sullivan, J. Sosman, 2013 .